Impact of Delta Model of End Stage Liver Disease (MELD) in High MELD Liver Transplant Recipients
HDMELD in LT
Delta MELD as a Predictor of Decreased Survival in High MELD Liver Transplant Recipients
1 other identifier
observational
446
2 countries
2
Brief Summary
Liver transplantation (LT) represents an important curative option for end stage liver disease such as decompensated cirrhosis, which remains a major challenge for today's health care system. The Model for End-Stage Liver Disease (MELD) is a worldwide-established scoring system for the evaluation of the severity of liver disease in allocation processes. However, the interpretation of MELD in clinical practice, particularly with regard to prioritizing potential liver transplant recipients, has revealed some hazards. These include the adaptation of MELD based on patient's characteristics, e.g. the presence of hepatocellular carcinoma, kidney failure and cardiovascular disease. In addition, the remaining paucity of organ donors contributes to a rising number of transplantations of high MELD recipients. This leads to the risk of impaired outcomes, especially considering the interaction of additional donor and recipient risk factors, such as extended cold preservation, kidney function and warm ischemia. For a certain patient cohort living donation might represent a feasible approach as reported previously for high MELD patients. Overall, the interaction of donor and recipient characteristics on the outcomes after LT in high MELD patients remains a scarcely investigated field. Therefore, the identification of factors influencing patient's outcomes after orthotopic liver transplantation becomes increasingly important, especially in high MELD recipients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2010
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedFirst Submitted
Initial submission to the registry
April 24, 2026
CompletedFirst Posted
Study publicly available on registry
May 6, 2026
CompletedMay 6, 2026
May 1, 2026
15 years
April 24, 2026
May 1, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
overall mortality of LT recipients
overall mortality of liver transplant recipients
minimal follow up of 12 months up to fifteen years
Secondary Outcomes (1)
Perioperative lenght of intensive care unit (ICU) stay
perioperative ICU stay, measured in days following liver transplantation maximal 24 weeks
Other Outcomes (1)
postoperative assessment of liver function
laboratory values at routine follow-up appointments within 1 year following LT; usually at one, three, six and twelve months
Study Arms (2)
DMELD+
liver transplant recipients with a positive delta MELD
DMELD-
liver transplant recipients without delta MELD
Eligibility Criteria
patients who underwent LT between 2010 and 2025 who were listed with a high MELD at the time of LT ( above 30). LT-R who had a high change of MELD ( above 10 points within 30 days) were assigned to the DMELD+ group, LT recipients without this accelaration were assigned to the DMELD- group.
You may qualify if:
- first LT
- age above 18 years
- completeness of dataset
- liver only
You may not qualify if:
- second or higher LT
- age below 18 years
- incomplete dataset
- combined transplant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Jenalead
- University Health Network, Torontocollaborator
Study Sites (2)
Toronto General Hospital
Toronto, Ontario, M5G 2C4, Canada
Jena University Hospital
Jena, Thueringia, 07747, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
April 24, 2026
First Posted
May 6, 2026
Study Start
January 1, 2010
Primary Completion
December 31, 2024
Study Completion
December 31, 2025
Last Updated
May 6, 2026
Record last verified: 2026-05